Subscribe
17 November 2017Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility